Ascendis increases expenses shortly before moment of truth

The US FDA will announce its decision on Ascendis Pharma's first drug on June 25 at the latest, and the firm is getting everything ready for a possible launch.

Photo: Kevin Grønnemann

The last month of Ascendis' second quarter will be eventful for the Danish biotech company listed in the US.

On June 25 at the latest, the US Food and Drug Administration (FDA) will make a decision on Ascendic's first commercial product Transon hgh, which is also known as lonapegsomatropin. The FDA is currently assessing the drug as a treatment for children with growth hormone deficiency (GHD).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs